Hello,
Financial Review Smart Investor magazine has Cellestis as a
'Small Cap Bargain' in the current issue, they list 25 companies which
have a financial health rating "strong"
The article headlines with "If you get in early on some of these
small-cap bargains you could hitch a ride to the corporate penthouse"
There is a fairly long description on what to look for in smaller
companies and brief specific coverage of each company.
Cellestis
"This biotechnology firm produces new blood test technology for
treatment of TB...Its Quantiferon products are in use worldwide...
It turned its first profit in 2008 and recorded strong growth in the first
half."
Martin
Financial Review Smart Investor magazine has Cellestis as a
'Small Cap Bargain' in the current issue, they list 25 companies which
have a financial health rating "strong"
The article headlines with "If you get in early on some of these
small-cap bargains you could hitch a ride to the corporate penthouse"
There is a fairly long description on what to look for in smaller
companies and brief specific coverage of each company.
Cellestis
"This biotechnology firm produces new blood test technology for
treatment of TB...Its Quantiferon products are in use worldwide...
It turned its first profit in 2008 and recorded strong growth in the first
half."
Martin
It's just a little bit nice to see that we are not alone in recognising the value in Cellestis.
(Even if they have got what Cellestis does slightly wrong)
(Even if they have got what Cellestis does slightly wrong)
No comments:
Post a Comment